We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Earnings Estimates Moving Higher for BeiGene (BGNE): Time to Buy?
Read MoreHide Full Article
BeiGene, Ltd. (BGNE - Free Report) is a biopharmaceutical company focused on developing and commercializing molecularly targeted and immuno-oncology drugs for cancer treatment, that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on BGNE’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that BeiGene could be a solid choice for investors.
Current Quarter Estimates for BGNE
In the past 30 days, four estimates have gone higher for BeiGene while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of $2.90 per share 30 days ago, to a loss of $2.47 today, a move of 14.8%.
Current Year Estimates for BGNE
Meanwhile, BeiGene’s current year figures are also looking quite promising, with five estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of $10.86 per share 30 days ago to a loss of $9.84 per share today, an increase of 9.4%.
The stock has also started to move higher lately, adding 32.6% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So, investors may want to consider this Zacks Rank #2 (Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Earnings Estimates Moving Higher for BeiGene (BGNE): Time to Buy?
BeiGene, Ltd. (BGNE - Free Report) is a biopharmaceutical company focused on developing and commercializing molecularly targeted and immuno-oncology drugs for cancer treatment, that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on BGNE’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that BeiGene could be a solid choice for investors.
Current Quarter Estimates for BGNE
In the past 30 days, four estimates have gone higher for BeiGene while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of $2.90 per share 30 days ago, to a loss of $2.47 today, a move of 14.8%.
Current Year Estimates for BGNE
Meanwhile, BeiGene’s current year figures are also looking quite promising, with five estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of $10.86 per share 30 days ago to a loss of $9.84 per share today, an increase of 9.4%.
BeiGene, Ltd. Price and Consensus
BeiGene, Ltd. Price and Consensus | BeiGene, Ltd. Quote
Bottom Line
The stock has also started to move higher lately, adding 32.6% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So, investors may want to consider this Zacks Rank #2 (Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>